Interferon decreases serum lipid peroxidation products of hepatitis C patients.
Thiobarbituric acid reactive substances (TBARS) concentration in serum has been determined in healthy subjects and in patients suffering acute hepatitis and chronic cases of hepatitis C. Treatment with interferon of the chronic active hepatitis C patients, 5 x 10(6) U three times a week during 2 months, led in those patients whose SGPT activity normalized in serum, to a concomitant decrease in serum TBARS content. The possible theoretical involvement of peroxidation and antioxidants in this beneficial effect of interferon in hepatitis C patients is discussed. The results presented confirm the value of TBARS as laboratory test in the management of liver diseases and as a useful tool for the study of pathogenic and/or therapeutic mechanisms of this viral infection.
Higueras
V
V
Department of Physiology, School of Medicine and Dentistry, University of Valencia, Spain.
Raya
A
A
Rodrigo
J M
JM
Serra
M A
MA
Romá
J
J
Romero
F J
FJ
D000208:Acute Disease; D015658:HIV Infections / Q000097:blood; D006505:Hepatitis / Q000097:blood / Q000628:therapy*; D006526:Hepatitis C / Q000097:blood / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000097:blood / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D015227:Lipid Peroxidation; D008055:Lipids / Q000097:blood*; D013482:Superoxide Dismutase / Q000378:metabolism; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism
D008055:Lipids; D017392:Thiobarbituric Acid Reactive Substances; D007372:Interferons; D013482:Superoxide Dismutase